Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Switching between intravenous and oral pantoprazole
Autore:
Pisegna, JR;
Indirizzi:
Univ Calif Los Angeles, CURE Digest Dis Res Ctr, VA Greater Los Angeles Healthcare Syst, Div Gastroenterol & Hepatol, Los Angeles, CA 90073 USA Univ Calif Los Angeles Los Angeles CA USA 90073 Los Angeles, CA 90073 USA
Titolo Testata:
JOURNAL OF CLINICAL GASTROENTEROLOGY
fascicolo: 1, volume: 32, anno: 2001,
pagine: 27 - 32
SICI:
0192-0790(200101)32:1<27:SBIAOP>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
GASTROESOPHAGEAL REFLUX DISEASE; PROTON-PUMP INHIBITORS; ZOLLINGER-ELLISON SYNDROME; STRESS-ULCER PROPHYLAXIS; GASTRIC-ACID SECRETION; NONCARDIAC CHEST PAIN; PEPTIC-ULCER; INTRAGASTRIC PH; DOUBLE-BLIND; OMEPRAZOLE SUSPENSION;
Keywords:
proton pump; pantoprazole; gastroesophageal reflux; Zollinger-Ellison syndrome; peptic ulcer; stress ulcer; syndrome; acid aspiration;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
62
Recensione:
Indirizzi per estratti:
Indirizzo: Pisegna, JR Univ Calif Los Angeles, CURE Digest Dis Res Ctr, VA Greater Los Angeles Healthcare Syst, Div Gastroenterol & Hepatol, Bldg 115,Room 315,1301 WilshireBlvd, Los Angeles, CA 90073 USA Univ Calif Los Angeles Bldg 115,Room 315,1301 Wilshire Blvd Los Angeles CA USA 90073
Citazione:
J.R. Pisegna, "Switching between intravenous and oral pantoprazole", J CLIN GAST, 32(1), 2001, pp. 27-32

Abstract

Proton pump inhibitors (PPIs) are the most effective antisecretory drugs available for controlling gastric acid acidity and volume. They are the drugs of choice in the treatment of moderate-to-severe gastroesophageal reflux disease, hypersecretory disorders, and peptic ulcers. Currently in the United States, they are only available in an oral formulation. However, pantoprazole will soon be available in an intravenous formulation and will extend the power of PPIs to inpatient hospital settings. Intravenous pantoprazole has been shown to be effective and safe in clinical trials. Intravenous pantoprazole is indicated for the treatment of patients who require PPI therapy but who are unable to take oral medication. Intravenous pantoprazole has been shown to maintain acid suppression in patients switched from oral PPIs, so no change in dosage is required when switching from one formulation tothe other. Potential hospital-based uses for intravenous PPI therapy include perioperative use as prophylaxis for acid aspiration syndrome during induction of anesthesia, prophylaxis for stress-related mucosal disease, and management of gastrointestinal bleeding from stress or acid peptic disease.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 21:28:06